Campbell Grieve

Prolific Machines is ushering in a new era of biotechnology with light. We harness light to produce everyday essentials more efficiently, from food and lifesaving drugs to novel biosolutions. Our first-of-its-kind photomolecular biology platform delivers unprecedented control, precisely guiding cellular behavior when and where it matters most. Unlike existing tools used to control biology, our technology unlocks dynamic control over virtually any cellular function in any cell type. We are enabling partners to unlock robust efficiency, quality, reproducibility, and sustainability advantages across pharmaceuticals, nutritional and therapeutic proteins, cellular agriculture, and more. To learn more, visit prolific-machines.com. Contact partners@prolific-machines.com to co-develop the future of biology.

Nimble is the leading global collaborator in delivering actionable intelligence from the small intestine of the GI tract. We are actively partnering with industry leaders offering real-time access to the novel data-rich environment of the small intestine via a passive capsule sampling approach, catalyzing innovation in therapeutics and diagnostics.

The microbiome is the new frontier gut health and changes to your microbiome signature is now being understood as a central conduit of health and disease. IBD, IBS, Crohns, colitis, type I diabetes, arthritis, metabolic syndrome, and several autoimmune disorders have all been associated with microbiome changes also known as dysbiosis. When you total the number of individuals affected by these diseases, over 80% Americans suffer from dysbiosis annually. With this much science there still arent real solutions for dysbiosis. And since dysbiosis is the result of changes to the 1000s different microbes of our gut it is nearly impossible to find the right remedy for your specific dysbiosis. Sun Genomics is empowering the consumer to educate themselves about their microbiome signature and make informed, as well as transparent, product selections to manage their dysbiosis. We are helping consumers realize the power of their microbiota through genomics, probiotics, microbiology, informatics, and software.

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting toxic forms of cholesterol, using rationally designed molecules, to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration.

Fonterra Cooperative Group is the worlds largest exporter of dairy products, a leader in dairy science and innovation, and a partner to many of the worlds leading food companies. Fonterra is headquartered in New Zealand, with offices in more than 40 countries around the world.

Prolific Machines is ushering in a new era of biotechnology with light. We harness light to produce everyday essentials more efficiently, from food and lifesaving drugs to novel biosolutions. Our first-of-its-kind photomolecular biology platform delivers unprecedented control, precisely guiding cellular behavior when and where it matters most. Unlike existing tools used to control biology, our technology unlocks dynamic control over virtually any cellular function in any cell type. We are enabling partners to unlock robust efficiency, quality, reproducibility, and sustainability advantages across pharmaceuticals, nutritional and therapeutic proteins, cellular agriculture, and more. To learn more, visit prolific-machines.com. Contact partners@prolific-machines.com to co-develop the future of biology.

Nimble is the leading global collaborator in delivering actionable intelligence from the small intestine of the GI tract. We are actively partnering with industry leaders offering real-time access to the novel data-rich environment of the small intestine via a passive capsule sampling approach, catalyzing innovation in therapeutics and diagnostics.

The microbiome is the new frontier gut health and changes to your microbiome signature is now being understood as a central conduit of health and disease. IBD, IBS, Crohns, colitis, type I diabetes, arthritis, metabolic syndrome, and several autoimmune disorders have all been associated with microbiome changes also known as dysbiosis. When you total the number of individuals affected by these diseases, over 80% Americans suffer from dysbiosis annually. With this much science there still arent real solutions for dysbiosis. And since dysbiosis is the result of changes to the 1000s different microbes of our gut it is nearly impossible to find the right remedy for your specific dysbiosis. Sun Genomics is empowering the consumer to educate themselves about their microbiome signature and make informed, as well as transparent, product selections to manage their dysbiosis. We are helping consumers realize the power of their microbiota through genomics, probiotics, microbiology, informatics, and software.

Cyclarity Therapeutics, Inc., is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting toxic forms of cholesterol, using rationally designed molecules, to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis, hypercholesterolemia, heart failure, and macular degeneration.